These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 20121197)

  • 1. Structure based drug design: development of potent and selective factor IXa (FIXa) inhibitors.
    Wang S; Beck R; Burd A; Blench T; Marlin F; Ayele T; Buxton S; Dagostin C; Malic M; Joshi R; Barry J; Sajad M; Cheung C; Shaikh S; Chahwala S; Chander C; Baumgartner C; Holthoff HP; Murray E; Blackney M; Giddings A
    J Med Chem; 2010 Feb; 53(4):1473-82. PubMed ID: 20121197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of benzothiophene template as potent factor IXa (FIXa) inhibitors in thrombosis.
    Wang S; Beck R; Blench T; Burd A; Buxton S; Malic M; Ayele T; Shaikh S; Chahwala S; Chander C; Holland R; Merette S; Zhao L; Blackney M; Watts A
    J Med Chem; 2010 Feb; 53(4):1465-72. PubMed ID: 20121198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SAR and factor IXa crystal structure of a dual inhibitor of factors IXa and Xa.
    Smallheer JM; Alexander RS; Wang J; Wang S; Nakajima S; Rossi KA; Smallwood A; Barbera F; Burdick D; Luettgen JM; Knabb RM; Wexler RR; Jadhav PK
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5263-7. PubMed ID: 15454208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urethanyl-3-amidinophenylalanine derivatives as inhibitors of factor Xa. X-ray crystal structure of a trypsin/inhibitor complex and modeling studies.
    Sperl S; Bergner A; Stürzebecher J; Magdolen V; Bode W; Moroder L
    Biol Chem; 2000 Apr; 381(4):321-9. PubMed ID: 10839461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.
    Ewing WR; Becker MR; Manetta VE; Davis RS; Pauls HW; Mason H; Choi-Sledeski YM; Green D; Cha D; Spada AP; Cheney DL; Mason JS; Maignan S; Guilloteau JP; Brown K; Colussi D; Bentley R; Bostwick J; Kasiewski CJ; Morgan SR; Leadley RJ; Dunwiddie CT; Perrone MH; Chu V
    J Med Chem; 1999 Sep; 42(18):3557-71. PubMed ID: 10479288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation on the binding mode of benzothiophene analogues as potent factor IXa (FIXa) inhibitors in thrombosis by CoMFA, docking and molecular dynamic studies.
    Hao M; Li Y; Zhang SW; Yang W
    J Enzyme Inhib Med Chem; 2011 Dec; 26(6):792-804. PubMed ID: 21381886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Na+ site in blood coagulation factor IXa: effect on catalysis and factor VIIIa binding.
    Schmidt AE; Stewart JE; Mathur A; Krishnaswamy S; Bajaj SP
    J Mol Biol; 2005 Jul; 350(1):78-91. PubMed ID: 15913649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor.
    Roehrig S; Straub A; Pohlmann J; Lampe T; Pernerstorfer J; Schlemmer KH; Reinemer P; Perzborn E
    J Med Chem; 2005 Sep; 48(19):5900-8. PubMed ID: 16161994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-Amidinoindoles as dual inhibitors of coagulation factors IXa and Xa.
    Batt DG; Qiao JX; Modi DP; Houghton GC; Pierson DA; Rossi KA; Luettgen JM; Knabb RM; Jadhav PK; Wexler RR
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5269-73. PubMed ID: 15454209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.
    Maduskuie TP; McNamara KJ; Ru Y; Knabb RM; Stouten PF
    J Med Chem; 1998 Jan; 41(1):53-62. PubMed ID: 9438022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-Amidinobenzo[b]thiophenes as dual inhibitors of factors IXa and Xa.
    Qiao JX; Cheng X; Modi DP; Rossi KA; Luettgen JM; Knabb RM; Jadhav PK; Wexler RR
    Bioorg Med Chem Lett; 2005 Jan; 15(1):29-35. PubMed ID: 15582405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Structure Based Study of Selective Inhibition of Factor IXa over Factor Xa.
    Kundu S; Wu S
    Molecules; 2021 Sep; 26(17):. PubMed ID: 34500804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosite occupation by heparin enhances the reactivity of blood coagulation factor IXa.
    Neuenschwander PF
    Biochemistry; 2004 Mar; 43(10):2978-86. PubMed ID: 15005634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors.
    Jones P; Bottomley MJ; Carfí A; Cecchetti O; Ferrigno F; Lo Surdo P; Ontoria JM; Rowley M; Scarpelli R; Schultz-Fademrecht C; Steinkühler C
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3456-61. PubMed ID: 18440229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and optimization of p38 inhibitors via computer-assisted drug design.
    Goldberg DR; Hao MH; Qian KC; Swinamer AD; Gao DA; Xiong Z; Sarko C; Berry A; Lord J; Magolda RL; Fadra T; Kroe RR; Kukulka A; Madwed JB; Martin L; Pargellis C; Skow D; Song JJ; Tan Z; Torcellini CA; Zimmitti CS; Yee NK; Moss N
    J Med Chem; 2007 Aug; 50(17):4016-26. PubMed ID: 17658737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a novel class of potent and selective FIXa inhibitors.
    Zhang T; Andre P; Bateman TJ; Chen YH; Desai K; Ellsworth K; Geissler WM; Guo L; Hruza A; Jian T; Meng D; Parker DL; Qian X; Reichert P; Sherer EC; Shu M; Smith CJ; Sonatore LM; Tschirret-Guth R; Nolting AF; Orr R; Campeau LC; Araki K; Nishimura T; Sakurada I; Wood HB
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4945-4949. PubMed ID: 25978966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides.
    Chan C; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chaudry L; Chung CW; Convery MA; Hamblin JN; Johnstone L; Kelly HA; Kleanthous S; Patikis A; Patel C; Pateman AJ; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE; Whitworth C; Young RJ; Zhou P
    J Med Chem; 2007 Apr; 50(7):1546-57. PubMed ID: 17338508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (R)-3-Amidinophenylalanine-derived inhibitors of factor Xa with a novel active-site binding mode.
    Mueller MM; Sperl S; Stürzebecher J; Bode W; Moroder L
    Biol Chem; 2002; 383(7-8):1185-91. PubMed ID: 12437104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Converting blood coagulation factor IXa into factor Xa: dramatic increase in amidolytic activity identifies important active site determinants.
    Hopfner KP; Brandstetter H; Karcher A; Kopetzki E; Huber R; Engh RA; Bode W
    EMBO J; 1997 Nov; 16(22):6626-35. PubMed ID: 9362477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.
    Xu G; Searle LL; Hughes TV; Beck AK; Connolly PJ; Abad MC; Neeper MP; Struble GT; Springer BA; Emanuel SL; Gruninger RH; Pandey N; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA; Greenberger LM
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3495-9. PubMed ID: 18508264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.